A Study of Eloralintide (LY3841136) in Healthy Participants

What Was Tested

This registered phase 1 trial tested Eloralintide.

The main purpose of this study is to learn about safety, tolerability and how well the body processes two different eloralintide solutions.

Participation in this study will last about 13 weeks, including screening, inpatient treatment, and follow-up.

It had two arms (groups): Eloralintide (Reference) (active comparator) and Eloralintide (Test) (experimental).

Participants will receive eloralintide reference formulation administered subcutaneously (SC).

Participants will receive eloralintide test formulation administered SC.

The registry classes the interventions as drug.

Who Took Part

The registry lists 58 planned participants were the target.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Are overtly healthy as determined by medical evaluation. Have a body mass index (BMI) within the range of 20.0 to 32.0 kilogram per square meter (kg/m2), inclusive.

The full record lists 2 inclusion and 8 exclusion criteria; among the exclusions: have known allergies to related compounds of eloralintide, or any of the components of the formulations; have a history or presence of a gastrointestinal (gi) disorder or previous surgery that impacts gastric emptying for example, gastric bypass surgery or pyloric stenosis; have taken approved or investigational medication for weight loss, including glucagon-like peptide-1 receptor agonists (glp-1 ras), within the previous 3 months of study screening.

How the Study Was Run

Design: randomized, parallel-group and open-label.

The participants were allocated by chance, so the Eloralintide group and the comparison group should start out alike.

The Eloralintide group and the comparison group ran side by side rather than switching.

Being open-label, the Eloralintide study did not mask who received what.

It started in 2026-07-20 with completion listed for 2026-10.

It ran at 2 sites in United States (2).

Its stated primary purpose is basic science.

What Was Measured

Researchers chose this as the main measure: PK: Maximum Concentration (Cmax) of Eloralintide (time frame: Predose on Day 1 through Day 57).

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Eloralintide in 58 people.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Eloralintide compound page, all human trials.